Actively Recruiting
Phase 2 Randomized Study Evaluating Safety and Immune Response of mRNA-1283 Vaccine in Children 6 Months to Under 12 Years
Led by ModernaTX, Inc. · Updated on 2026-10-29
300
Participants Needed
31
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating two dose levels of mRNA-1283 in children aged 6 months to less than 12 years to find the best dose for each age group. The study is a phase 2, randomized, observer-blind trial comparing mRNA-1283 with mRNA-1273 as an active comparator. It aims to assess safety, immune response, and side effects related to these vaccines against SARS-CoV-2. The study includes two cohorts Cohort 1 involves children aged 2 to less than 12 years receiving a single intramuscular dose of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. Cohort 2 includes children aged 6 months to less than 2 years who are unvaccinated against COVID-19 and receive two intramuscular doses 28 days apart of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. The study compares the immune responses and side effects between these groups. Participants will be monitored for local and systemic adverse reactions for 7 days after vaccination and unsolicited adverse events for up to 28 days. Serious and medically attended adverse events will be tracked throughout the study, which lasts up to 13 months. Researchers will measure antibody levels against SARS-CoV-2 at specific visits to evaluate immune response. The trial includes regular medical evaluations and safety assessments to ensure participant well-being.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
Research Team
M
Moderna WeCare Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here